Cervical Cancer

Women who do not engage in regular physical activity have an increased risk of developing cervical cancer, according to a new study

The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.

In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.

Small- and large-cell neuroendocrine tumors of the cervix are exceedingly rare and exceedingly aggressive.

Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.

A review by the European Medicines Agency shows that the HPV vaccine does not cause complex regional pain syndrome and postural orthostatic tachycardia syndrome.

An investigational vaccine has shown activity as a therapeutic treatment for high-grade pre-cancerous cervical lesions caused by the human papillomavirus.

Fertility preservation for patients diagnosed with early-stage cervical cancer is feasible and has gained acceptance within the gynecologic oncology community.

Detection of cervical lesions among young women has decreased since the introduction of HPV vaccines and guidelines calling for reduced cervical cancer screening.

There is good evidence that angiogenesis plays a central role in cervical cancer pathogenesis, suggesting a strong rationale for adding anti-angiogenesis agents to chemotherapeutic agents for the treatment of this disease.

The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.

The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.

Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.

A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.

Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.

Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.

Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 is an appropriate treatment option for women aged 25 years and younger.

A test for dangerous strains of high-risk HPV using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification.

Multiple lesion-directed biopsies can drastically improve the sensitivity of colposcopy in women referred for abnormal cervical cancer screening.

More than 11% of all eligible women had not been screened for cervical cancer in the past 5 years, according to a study by researchers at the CDC.

Nurses trained in the visual inspection with acetic acid cervical cancer screening method were able to successfully perform colposcopy and detect cervical lesions.

Vaccines including that for HPV, which helps prevent cervical cancer, show no association at all with multiple sclerosis or other CNS demyelinating syndromes.

Hydronephrosis is associated with substantial morbidity in patients with cervical cancer, and is potentially associated with poorer survival as well.

A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.

Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.

The US Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of patients with recurrent or metastatic cervical cancer.

The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.

An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.

A new study has demonstrated that a therapeutic vaccine against HPV can stimulate an immune response and regression of high-grade cervical dysplasia, a precursor to cervical cancer in women with an HPV infection.

An analysis of four randomized clinical trials from Europe shows that HPV-based screening resulted in a greater long-term protection from invasive cervical cancer compared with a Pap test.